Analyzing...
Loading company...
Alkem Laboratories Ltd. engages in the development, manufacture, and sale of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 16,871 full-time employees. The company went IPO on 2015-12-23. The firm is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The firm offers its products across various therapeutic areas, such as Anti Infective, Dermatology, Diabetology, Cardiology, Gastroenterology, Osteoporosis, Rheumatology, central nervous system (CNS), Oncology, Urology, Gynecology, and Vitamins, Mineral and Nutrition. Its product range includes Rx Products, Alkem Generics and OTC Product. The Company’s product portfolio includes brands, such as Clavam, Pan, Pan-D, Taxim-O, A To Z NS, Xone, Taxim, Gemcal, Pipzo and Ondem. The firm operates through a segment, Pharmaceuticals. The company has approximately 21 manufacturing facilities at multiple locations in India and the United States. The firm has approximately 800 brands and operates in 40 countries.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹14,712 Cr revenue.
COGS 34.6%, employees 19.3%.
“we gave an overall guidance of a double digit kind of growth assuming the market grows at around 8% to 8.”
“I see somewhere between 19.”
“we'll continue to outperform the market at least by 100 to 150 basis points.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 16.7%▲ | 10.3% |
| ROCE | 18.8%▲ | 13.7% |
| Net Margin | 15.0%▲ | 7.6% |
| EBITDA Margin | 22.3%▲ | 15.4% |
| Debt To Equity | 0.12x▼ | 0.15x |
| Rev Growth 3yr | 9.0%▼ | 10.0% |
| EPS Growth 3yr | 32.7%▲ | 16.0% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹14,712 Cr +13.5% | ₹12,965 Cr +2.3% | ₹12,668 Cr +9.2% | ₹11,599 Cr +9.1% | ₹10,634 Cr +20.0% | ₹8,865 Cr +6.2% | ₹8,344 Cr +13.4% | ₹7,357 Cr |
| Other Income | ₹583 Cr +18.1% | ₹494 Cr +58.8% | ₹311 Cr +43.9% | ₹216 Cr +32.8% | ₹163 Cr -30.3% | ₹233 Cr +123.8% | ₹104 Cr +18.8% | ₹88 Cr |
| Total Income | ₹15,296 Cr +13.7% | ₹13,458 Cr +3.7% | ₹12,978 Cr +9.8% | ₹11,815 Cr +9.4% | ₹10,797 Cr +18.7% | ₹9,098 Cr +7.7% | ₹8,449 Cr +13.5% | ₹7,445 Cr |
| COGS | ₹5,093 Cr +6.9% | ₹4,764 Cr -3.5% | ₹4,938 Cr +0.6% | ₹4,907 Cr +17.4% | ₹4,180 Cr +19.5% | ₹3,498 Cr +4.6% | ₹3,345 Cr +13.6% | ₹2,945 Cr |
| ₹12,250 Cr +12.1% | ₹10,931 Cr +0.9% | ₹10,834 Cr +4.1% | ₹10,408 Cr +16.4% | ₹8,938 Cr +23.2% | ₹7,256 Cr +0.9% | ₹7,189 Cr +10.8% | ₹6,490 Cr | |
| Profit Before Tax | ₹2,871 Cr +13.6% | ₹2,527 Cr +24.9% | ₹2,023 Cr +55.1% | ₹1,305 Cr -29.3% | ₹1,844 Cr +0.1% | ₹1,842 Cr +46.2% | ₹1,260 Cr +32.0% | ₹955 Cr |
| Exceptional Items | (₹175 Cr) | ₹0.00 Cr +100.0% | (₹121 Cr) -18.0% | (₹103 Cr) -588.2% | (₹15 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹518 Cr +66.5% | ₹311 Cr +46.9% | ₹212 Cr -29.0% | ₹298 Cr +81.7% | ₹164 Cr -26.9% | ₹224 Cr +103.1% | ₹110 Cr -39.0% | ₹181 Cr | |
| Net Profit | ₹2,351 Cr +6.1% | ₹2,215 Cr +22.3% | ₹1,811 Cr +79.9% | ₹1,007 Cr -40.1% | ₹1,680 Cr +3.9% | ₹1,618 Cr +40.8% | ₹1,149 Cr +48.6% | ₹774 Cr |
| Profit (Owners) | ₹2,302 Cr +6.3% | ₹2,165 Cr +20.6% | ₹1,796 Cr +82.5% | ₹984 Cr -40.2% | ₹1,646 Cr +3.8% | ₹1,585 Cr +40.6% | ₹1,127 Cr +48.2% | ₹761 Cr |
| Minority Interest | ₹49 Cr -1.1% | ₹50 Cr +218.0% | ₹16 Cr -30.7% | ₹23 Cr -34.8% | ₹35 Cr +6.0% | ₹33 Cr +47.3% | ₹22 Cr +69.4% | ₹13 Cr |
| Other Comprehensive Income | ₹184 Cr +832.0% | ₹20 Cr -1.6% | ₹20 Cr -82.6% | ₹115 Cr +236.6% | ₹34 Cr ↑ Recovery | (₹34 Cr) ↓ Decline | ₹27 Cr -13.4% | ₹31 Cr |
| EPS | ₹192.52 | ₹181.11 | ₹150.19 | ₹82.31 | ₹137.63 | ₹132.57 | ₹94.26 | ₹63.61 |
| Diluted Shares | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr |
| Profit Or Loss Of Associates | (₹2 Cr) -217.6% | (₹0.62 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Alkem Laboratories Limited has informed the Exchange about disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2...
Alkem Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Alkem Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 27, 2026
Alkem Laboratories Limited has informed the Exchange about Business Responsibility and Sustainability Report for financial year ended 31st March, 2026.
Alkem Laboratories Limited has informed the Exchange about Schedule of meet
Alkem Laboratories Limited has informed the Exchange regarding Resignation of Dr. Jitendra Singh Huda as Other of the company w.e.f. July 23, 2026.
Alkem Laboratories Limited has informed the Exchange about Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ( SEBI LODR Regulations...
Alkem Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Alkem Laboratories Limited has informed the Exchange about Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ( SEBI LODR Regulations...
Alkem Laboratories Limited has informed the Exchange regarding Notice of Court Convened General Meeting to be held on August 17, 2026
Alkem Laboratories Limited has informed the Exchange about Action(s) taken or orders passed
Alkem Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Alkem Laboratories Limited has informed the Exchange about Schedule of meet
Alkem Laboratories Limited has informed the Exchange about Schedule of meet
Alkem Laboratories Limited has informed the Exchange about Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ( SEBI LODR Regulations...